cetuximab
View Patient InformationA recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.
| Synonym: | Anti-EGFR Monoclonal Antibody Anti-Epidermal Growth Factor Receptor Monoclonal Antibody C225 monoclonal antibody cetuximab biosimilar CDP-1 cetuximab biosimilar CMAB009 cetuximab biosimilar KL 140 Chimeric Anti-EGFR Monoclonal Antibody Chimeric Monoclonal Antibody C225 Immunoglobulin G1, anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 gamma1-chain), disulfide with human-mouse monoclonal C225 kappa-chain, dimer monoclonal antibody C225 |
|---|---|
| US brand name: | Erbitux |
| Abbreviation: | Chimeric MoAb C225 MOAB C225 |
| Code name: | C225 IMC-C225 |
| IND number: | 11460 3610 |
| NSC code: | 714692 |